CytoDyn Inc. a late-stage biotechnology company disclosed that an independent Data Safety Monitoring Committee (“DSMC”), completed its first safety review of the ongoing Phase 3 clinical trial (CD12) in patients with severe and critical COVID-19 and reported it saw no...